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Objectives: The objective of this study was to determine the effectiveness of visual 
aids for translation of the Spasticity Symptom Assessment-Upper Limb (SSA-UL) 
questionnaire as an additional support tool for linguists. Some items in the SSA-UL 
concern specific physical positions experienced by stroke patients, due to muscle 
spasticity. It was theorized that translation would be improved by providing transla-
tors with a visual of physical positions, supplementing a textual definition, which 
may be complex and open to varied interpretations. MethOds: The SSA-UL was 
translated into 14 languages. Translators were provided a textual definition and 
images of the following physical positions: (1) hand clenching, (2) finger clenching, 
(3)hand curling and (4) finger curling. Back-translations were analyzed for conceptual 
equivalency with the source text. In addition, each translator (n= 28) was given a 
questionnaire about the effectiveness of the visual aids. Results: Translations of 
hand clenching and finger clenching were conceptually equivalent to the source 100% 
of the time. For both hand and finger curling, only French-Canada and Polish-Poland 
struggled to find an equivalent translation, ultimately achieving a conceptually 
equivalent translation. German-Germany linguists had initially translated curling 
and clenching incorrectly, but utilized the images to revise the translation. Nineteen 
(19) linguists responded to the questionnaire. Fifteen (79%) found the visual aids 
helpful. For comparison, previous translations of other physical positions translated 
without visual aids were analyzed with a similar language sample. Bending was 
translated as conceptually equivalent to the source 83% (10/12) of the time, stooping 
58% (7/12) and feet dropping forwards 50% (6/12). cOnclusiOns: Back-translations 
showed that visual aids added value to the translation process. Linguists surveyed 
reported that the visual aids assisted them in finding the correct terminology for 
the physical positions. Moving forward, translation of questionnaires containing 
items about physical positions may benefit from visual aids.
PRM83
PsychoMetRic PRoPeRties of the bRief fatigUe inventoRy-shoRt foRM 
in systeMic lUPUs eRytheMatosUs
Al Sawah S.1, Tomaszewski E.L.2, Gemmen E.3, Naegeli A.1
1Eli Lilly and Company, Inc., Indianapolis, IN, USA, 2Quintiles, Pittsburgh, PA, USA, 3Quintiles, 
Rockville, MD, USA
Objectives: A 12-week prospective, observational study was conducted to evaluate 
the psychometric properties of the Brief Fatigue Inventory-Short Form (BFI-SF) and 
determine its appropriate use and performance for the measurement of fatigue 
in systemic lupus erythematosus (SLE) clinical trials. MethOds: Participants ≥ 18 
years, who self-reported a physician diagnosis of SLE (confirmed by medical record 
review) and active SLE demonstrated by a Systemic Lupus Activity Questionnaire 
(SLAQ) score ≥ 11 (0-44 scale), were recruited using a free electronic medication 
monitoring service. All participants completed the BFI-SF, Multidimensional 
Assessment of Fatigue (MAF), and Short Form-36 (SF-36) electronically at baseline, 
week 2, and week 12. Score distributions, internal consistency, test-retest reliability, 
and construct validity were evaluated. Results: A total of 122 participants were 
included in the study. The mean age was 45.7 years, 95.9% were female, and 68.9% 
were non-Hispanic white. Cronbach’s alpha were > 0.9 for all BFI-SF items. Test-
retest reliability of the BFI-SF showed a stable intraclass correlation for item #7 (ICC 
0.76), and BFI domain scores had higher correlations (around 0.5) than most items 
(around 0.3-0.4). Construct validity was measured by strength of the correlations 
of the BFI-SF severity domains and global scores, and was moderately positively 
correlated to the SLAQ score (r> 0.4). The domain and global scores were moderately 
negatively correlated to the SF-36 Vitality and Physical Function domains and SF-36 
Physical Component score (r< -0.3). The BFI-SF item #3 for worst fatigue was highly 
positively correlated to the MAF (r= 0.6). Patients with less severe fatigue (MAF≤ 36) 
scored lower than patients with more severe fatigue (MAF> 36) on all domains of the 
BFI-SF (total score, 4.66±1.55 vs. 6.80±1.13; p< 0.0001). cOnclusiOns: Assessment 
of fatigue severity as measured by the BFI-SF demonstrated validity and reliability 
in a sample of patients with moderate-to-severe SLE and may be used as a patient-
reported outcome tool in clinical trials.
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Objectives: Patient-reported outcome (PRO) instruments commonly used to meas-
ure fatigue in multiple sclerosis (MS) have not been developed according to the 2009 
FDA PRO guidance. A qualitative research study was conducted to develop a new 
PRO, according to the guidance, measuring fatigue symptoms and impacts in relaps-
ing MS (RMS). MethOds: Adult patients with relapsing-remitting MS (RRMS) were 
interviewed to elicit fatigue-related symptoms and impacts. Based on spontaneously 
reported symptoms, a draft PRO was developed. This was debriefed in cognitive 
interviews with further RRMS patients, and subsequently revised. Applicability of 
the PRO to other RMS populations was determined in content confirmation inter-
views with progressive-relapsing MS (PRMS) and relapsing secondary-progressive 
MS (RSPMS) patients. Institutional review board approval and participant informed 
consent were obtained before interviews. Results: Participants were representative 
of RMS patients in clinical studies and practice; most had mild-to-moderate disease. 
Concept elicitation and cognitive debriefing included 17 (mean±SD age 43.9±13.3 
[years]; 77% female) and 20 (47.0±12.0; 80% female) RRMS patients, respectively; con-
tent confirmation included 5 PRMS (52.6±12.5; 80% female) and 5 RSPMS (52.4±10.8; 
60% female) patients. Saturation of concepts was reached during concept elicitation. 
Cognitive debriefing confirmed that participants understood PRO instructions, items, 
Objectives: The quality-adjusted time without symptoms and toxicity (Q-TWiST) 
methodology has been used to assess the clinical benefits (prolonged [progres-
sion-free] survival) and costs (toxicities) of oncology therapies. This study was con-
ducted to systematically review and quantitatively summarize published Q-TWiST 
assessments of cancer treatments. MethOds: A systematic search and review was 
conducted in MEDLINE to identify original studies reporting the Q-TWiST informa-
tion—including time with toxicity (TOX), time before disease progression without 
toxicity (TWiST), and time in relapse after disease progression (REL)—for all oncol-
ogy treatment groups, as available. Utilities for Q-TWiST were also captured; when 
a base case for utilities was not selected in a study, the following was assumed: 
u(TWiST)= 1, u(REL)= 0.5, and u(TOX)= 0.5. The relative gain in Q-TWiST for active 
treatment arms was calculated as the difference in Q-TWiST divided by mean 
overall survival of control arm. Relative gains ≥ 10% and ≥ 15% were considered 
to be a clinically important and clearly clinically important difference, respec-
tively. Results: Upon review of 84 initially identified articles, 39 were excluded 
for the following reasons: no Q-TWiST was reported (n= 22), not oncology-related 
(n= 13), other reasons (n= 4). Forty-five studies were included and reported a total 
of 69 Q-TWiST comparisons across 10 cancers. The most commonly used utilities 
for Q-TWiST calculation were u(TWiST)= 1, u(REL)= 0.5, u(TOX)= 0.5 (n= 28, 62.2% of 
articles). Using base-case utility values, the mean (range) Q-TWiST gain was 5.2 
(-6.8 to 61) months and the mean relative gain was 9.0% (-13.3% to 60.0%); 41.8% 
and 17.9% of studies reported relative gains ≥ 10% and ≥ 15%, respectively. Applying 
u(REL)= u(TOX)= 0.5 to comparisons with sufficient data (n= 65), the mean standard-
ized Q-TWiST gain was 5.4 (-4.1 to 61) months and mean standardized relative gain 
was 8.2% (range -15.0% to 54.5%). cOnclusiOns: This review of Q-TWiST for cancer 
therapies can serve as benchmark against which future analyses can be compared.
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Objectives: The EQ-5D is often used to measure health utilities. Uncertainty in 
the EQ-5D scoring algorithm is routinely ignored. We aim to quantify the extent of 
uncertainty in the US EQ-5D-3L scoring algorithm, which was based on data from 
3773 respondents -- largest valuation study to date. MethOds: We re-fitted the 
US scoring algorithm using the same data and functional form as was originally 
used, omitting each health state in turn and examining the error in the predicted 
mean utilities. We then used a mixed effects model, including a random effect for 
health state, adopting a Bayesian perspective to estimate the predictive distribution 
of the mean utilities for health states not included in the valuation study (which 
captured 43 of 243 health states). This allowed us to estimate uncertainty in the scor-
ing algorithm. Results: The mean absolute error for predicted mean utilities on 
cross-validation was 0.033; the mean absolute error for a perfect model, accounting 
for sampling error in the observed mean utilities, would have been 0.01. The root 
mean squared error was 0.042; for a perfect model it would have been 0.013. The 
standard deviation for the random effect for health state was 0.03, suggesting that 
the width of the confidence interval for the mean utility for a randomly selected 
health state is around 0.12. The Bayesian model indicated that the width of the 95% 
credible interval for the mean utilities varied from 0.015 to 0.45, with a median width 
of 0.18 and interquartile range of 0.15 to 0.22. cOnclusiOns: EQ-5D health utilities 
are subject to considerable uncertainty (for comparison, the MID for EQ-5D utilities 
is 0.05 to 0.08). Other countries’ scoring algorithms are based on smaller sample 
sizes and so subject to greater uncertainty. This uncertainty should be accounted 
for when using EQ-5D health utilities in economic evaluations.
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Objectives: There is increasing clinical and research interest in monitoring 
functional outcomes, including occupational functioning, in people with Major 
Depressive Disorder (MDD). Self-rated scales are most practical for clinical settings, 
but there are few work functioning scales that have been validated in depressed 
populations. We now report further psychometric studies of the Lam Employment 
Absence and Productivity Scale (LEAPS), a brief 10-item self-report question-
naire. MethOds: Patients meeting DSM-IV criteria for MDD completed the LEAPS 
during initial assessment and following various treatment protocols in specialist 
outpatient and family practice settings, and other scales including the self-rated 
Sheehan Disability Scale (SDS) and Health and Work Performance Questionnaire 
(HPQ), and the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale. 
Standard statistical analyses for scale validation were conducted. Results: In a 
sample of 418 patients at baseline assessment, internal consistency was high, with 
Cronbach’s alpha of 0.93 (for the LEAPS total score) and 0.89 (for the productiv-
ity subscale). Convergent validity was supported by significant correlations of the 
LEAPS total score and productivity subscale with the SDS work/role item score 
(r= 0.49, 0.43, respectively, both p< 0.0001) and the HPQ Overall Performance score 
(r= -0.42, -0.53, respectively, both p< 0.0001). In a sample of 104 patients repeating the 
LEAPS within a 1 week period, excellent test-retest correlations were found (r= 0.95, 
p< 0.0001). In a sample of 176 patients assessed before and after 8 weeks of antide-
pressant treatment, the LEAPS showed good responsivity to change, with differences 
in means between CGI-I categories of Very Much Improved (LEAPS total score change 
= 10.7±5.5; productivity subscale change= 3.9±2.5), Much Improved (total= 8.3±4.5; 
subscale= 3.0±2.3) and Minimally Improved/No Change/Worse (total= 4.5±5.7; 
subscale= 1.4±2.9); differences were significant for both LEAPS total score change 
(ANOVA, F= 7.29, df= 2,83, p= 0.001) and for productivity subscale change (F= 4.07, 
df= 2,83, p= 0.021). cOnclusiOns: These data support the LEAPS as a valid, reliable 
and responsive instrument in patients with MDD.
